News

September 2015: AlveoliX awarded a CTI funding.

September 2015: AlveoliX awarded a CTI funding.

The Swiss Commission for Technology and Innovation (CTI) has awarded AlveoliX and its scientific partners from the ARTORG Center and the Inselspital a research grant to develop an advanced lung fibrosis-on-chip model to test anti-fibrotic compounds. Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with poor prognosis. Clinical evidence suggests that the mechanical strain induced by the respiration plays a key role in the progression of the disease. In contrast to current in-vivo and in-vitro models that poorly mimic key processes that take place in IPF.

By |September 13th, 2015|Allgemein|Kommentare deaktiviert für September 2015: AlveoliX awarded a CTI funding.

About the Author:

Comments are closed.